share_log

歌禮製藥-B：翌日披露報表

ASCLETIS-B: Next Day Disclosure Return

香港交易所 ·  Feb 8 05:08
Summary by Moomoo AI
歌禮製藥有限公司於2024年2月8日向香港聯合交易所有限公司提交了翌日披露報表，披露了自2023年12月19日至2024年2月8日期間的股份購回活動。根據報表，該公司在此期間共購回了66,756,000股普通股，佔其已發行股份的6.1405%。最後一次購回發生在2024年2月8日，當天購回了635,000股，每股價格介於HKD 1.68至HKD 1.75之間，總計耗資HKD 1,096,520。購回的股份尚未註銷。歌禮製藥確認，所有購回活動均獲得董事會正式授權批准，並符合香港聯交所的相關規則。
歌禮製藥有限公司於2024年2月8日向香港聯合交易所有限公司提交了翌日披露報表，披露了自2023年12月19日至2024年2月8日期間的股份購回活動。根據報表，該公司在此期間共購回了66,756,000股普通股，佔其已發行股份的6.1405%。最後一次購回發生在2024年2月8日，當天購回了635,000股，每股價格介於HKD 1.68至HKD 1.75之間，總計耗資HKD 1,096,520。購回的股份尚未註銷。歌禮製藥確認，所有購回活動均獲得董事會正式授權批准，並符合香港聯交所的相關規則。
ACEA PHARMACEUTICALS LIMITED FILED THE FOLLOWING DAY DISCLOSURE REPORT WITH THE HONG KONG STOCK EXCHANGE LIMITED ON 8 FEBRUARY 2024 DISCLOSING ITS SHARE REPURCHASE ACTIVITIES FOR THE PERIOD 19 DECEMBER 2023 TO 8 FEBRUARY 2024. According to the report, the company repurchased a total of 66,756,000 shares of ordinary shares during this period, representing 6.1405% of its issued shares. The last repurchase took place on February 8, 2024. 635,000 shares were repurchased on the same day, priced between HKD 1.68 and HKD 1.75, with a total cost of HKD 1,096,520. The repurchased shares have not been written off. ACARA PHARMACEUTICALS CONFIRMS THAT ALL BUYBACKS HAVE BEEN FORMALLY AUTHORISED BY THE BOARD OF DIRECTORS AND COMPLY WITH THE RELEVANT RULES OF THE HKEX.
ACEA PHARMACEUTICALS LIMITED FILED THE FOLLOWING DAY DISCLOSURE REPORT WITH THE HONG KONG STOCK EXCHANGE LIMITED ON 8 FEBRUARY 2024 DISCLOSING ITS SHARE REPURCHASE ACTIVITIES FOR THE PERIOD 19 DECEMBER 2023 TO 8 FEBRUARY 2024. According to the report, the company repurchased a total of 66,756,000 shares of ordinary shares during this period, representing 6.1405% of its issued shares. The last repurchase took place on February 8, 2024. 635,000 shares were repurchased on the same day, priced between HKD 1.68 and HKD 1.75, with a total cost of HKD 1,096,520. The repurchased shares have not been written off. ACARA PHARMACEUTICALS CONFIRMS THAT ALL BUYBACKS HAVE BEEN FORMALLY AUTHORISED BY THE BOARD OF DIRECTORS AND COMPLY WITH THE RELEVANT RULES OF THE HKEX.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more